文献速递白血病

TP53突变急性髓系白血病化疗耐药需要甲羟戊酸途径副产物香叶基香叶基焦磷酸来诱导适应性应激反应

Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
PubMed 文献 · Leukemia · 2025-07-09

TP53突变急性髓系白血病(TP53mut AML)中位生存仅6个月。RNA测序显示TP53mut AML的甲羟戊酸途径基因表达升高;同基因TP53mut AML细胞系和原代样本显示其对阿糖胞苷(AraC)耐药与甲羟戊酸途径活性升高、活性氧(ROS)诱导降低及线粒体质量增加和氧化磷酸化增强相关。他汀类预处理可逆转这些效应并增敏化疗;香叶基香叶基焦磷酸(GGPP)分支是耐药所必需,并具有调控谷胱甘肽以管理AraC诱导ROS的新功能。但单用他汀在体内和364例同时接受他汀与化疗的TP53mut AML患者回顾性研究中不足以完全逆转耐药。

要点

  • TP53mut AML的甲羟戊酸途径基因表达升高,其AraC耐药与途径活性升高、ROS诱导降低及线粒体质量增加相关。
  • 他汀类预处理可逆转上述效应并增敏TP53mut AML,GGPP分支为耐药所必需并调控谷胱甘肽管理AraC诱导的ROS。
  • 单用他汀在体内及364例TP53mut AML患者回顾性研究中不足以完全逆转化疗耐药。

核心结论

  • TP53mut AML对AraC的耐药需要甲羟戊酸途径副产物GGPP来诱导线粒体生物发生和谷胱甘肽调控等适应性应激反应。
  • 他汀类预处理可逆转这些效应并增敏TP53mut AML,但单用他汀在体内和回顾性研究中不足以完全逆转耐药。
  • 研究识别了成功靶向甲羟戊酸途径的临床场景和策略,以应对TP53mut AML的未满足需求。

研究设计与样本

  • 对纯化的AML患者样本进行RNA测序。
  • 使用新型同基因TP53mut AML细胞系和原代样本进行实验研究。
  • 回顾性研究纳入364例同时接受化疗和他汀治疗的TP53mut AML患者。

主要发现

  • TP53mut AML的甲羟戊酸途径基因表达高于对照。
  • TP53mut AML对AraC耐药与甲羟戊酸途径活性升高、ROS诱导降低、线粒体质量增加和氧化磷酸化增强相关。
  • 他汀类预处理逆转上述效应并增敏TP53mut AML。
  • GGPP分支为TP53mut AML化疗耐药所必需,并具有调控谷胱甘肽以管理AraC诱导ROS的新功能。
  • 单用他汀在体内和364例患者回顾性研究中不足以完全逆转化疗耐药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 单用他汀在体内和回顾性研究中不足以完全逆转化疗耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia with mutations in TP53 (TP53mut AML) is fatal with a median survival of 6 months. RNA sequencing on purified AML patient samples showed that TP53mut AML had higher expression of mevalonate pathway genes. Using novel, isogenic TP53mut AML cell lines and primary samples, we determined that TP53mut AML resistance to AML chemotherapy cytarabine (AraC) correlated with increased mevalonate pathway activity, a lower induction of reactive oxygen species (ROS), and a mitochondrial response with increased mitochondrial mass and oxidative phosphorylation. Pretreatment with the statin class of mevalonate pathway inhibitors reversed these effects and chemosensitized TP53mut AML. The geranylgeranyl pyrophosphate (GGPP) branch of the mevalonate pathway was required for TP53mut AML chemoresistance. In addition to its role in mitochondria biogenesis, we identified a novel function of GGPP in regulating glutathione for management of AraC-induced ROS. However, statins alone were inadequate to fully reverse chemoresistance in vivo and in a retrospective study of 364 TP53mut AML patients who received chemotherapy concurrently with a statin. Finally, we identified clinical settings and strategies to successfully target the mevalonate pathway, particularly to address the unmet need of TP53mut AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Skuli SJ, Bakayoko A, Kruidenier M, et al. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia. 2025. PMID: 40634510. doi:10.1038/s41375-025-02668-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。